Aurinia Pharmaceuticals (AUPH) Work In Process (2023 - 2026)

Aurinia Pharmaceuticals (AUPH) has 4 years of Work In Process data on file, last reported at $41.4 million in Q1 2026.

• Quarterly Work In Process fell 0.79% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.4 million (down 0.79% YoY) and the FY2025 annual result came in at $44.7 million, up 21.93% from the prior year.
• Work In Process eased to $41.4 million in Q1 2026, from $44.7 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $44.7 million in Q4 2025 to a low of $36.6 million in Q4 2024.
• A 4-year average of $41.1 million and a median of $41.7 million in 2025 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2024 — Work In Process dropped 2.01% — and 2025, when it rose 21.93%.
• Tracing AUPH's Work In Process over 4 years: stood at $37.4 million in 2023, then retreated by 2.01% to $36.6 million in 2024, then increased by 21.93% to $44.7 million in 2025, then retreated by 7.24% to $41.4 million in 2026.
• The last three Work In Process figures came in at $41.4 million (Q1 2026), $44.7 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.